Date: 2012-03-05
Type of information: Licensing agreement
Compound: PT20
Company: Phosphate Therapeutics (UK) Medical Research council - MRC (UK)
Therapeutic area: Metabolic diseases - Renal diseases - Kidney diseases
Type agreement: licensing
Action mechanism: PT20 is a novel phosphate binder with robust global IP protection that is based on adipate-doped iron oxide technology, allowing it to act as a ‘phosphate sponge’. Discovered and initially developed through clinical Phase 1 by MRC scientists based at the Human Nutrition Research Unit in Cambridge, UK; PT20 exhibits high specificity and efficacy in phosphate binding both in vitro and in vivo. In early studies PT20 appears to display characteristics that may position it as superior to current or known pipeline phosphate binders as it has the potential to overcome the key disadvantages in this class of therapeutics.
Disease: hyperphosphataemia
Details: Phosphate Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, has signed an exclusive agreement with the Medical Research Council (MRC) to acquire the global rights to PT20, a novel Phase 2 ready phosphate binder for the treatment of hyperphosphataemia. The PT20 programme was initially supported by funding from the MRC’s Development Gap Fund and this deal was negotiated by MRC Technology on behalf of MRC. At the same time funding of up to €10.5m has been secured from Inventages Venture Capital (Inventages) to complete the Phase 2 development of PT20.
Phosphate Therapeutics expects to initiate a confirmatory Phase I pharmacokinetic study in H2-2012 and initiate a Phase II dose-escalating, comparator study in 2013 for the treatment of hyperphosphataemia in patients with pre-dialysis and dialysis-dependent chronic kidney disease (CKD).
Financial terms:
Latest news:
